News & Updates
– Disparities, Such as Access to Healthcare, Comorbidities and Differences in TNBC Disease Biology Typically Drive Worse Clinical Outcomes in Black Women Excerpt from the Press Release: FOSTER CITY, Calif.–(BUSINESS WIRE)–Dec. 10, 2021– Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from the Phase 3 ASCENT study evaluating Trodelvy® (sacituzumab govitecan-hziy) in relapsed or refractory metastatic triple-negative breast…
Read More
ATA2271 targets difficult-to-treat solid tumors using proprietary 1XX CAR signaling and intrinsic PD-1 checkpoint inhibition technology Ongoing Phase 1 dose-escalation trial in advanced mesothelioma shows promising early safety and persistence of armored CAR T cells in patients Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy,…
Read More
– Trial to evaluate antigen suppression combined with immunomodulation as a functional cure regimen for chronic HBV – Excerpt from the Press Release: SAN FRANCISCO, Dec. 09, 2021 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in a Phase 2 clinical trial evaluating novel therapeutic combinations…
Read More
Excerpt from the Press Release: One of the more pressing calls-to-action in the aftermath of the COVID-19 pandemic has been the need to facilitate more accessible, effective, and seamless data sharing across the worldwide research community. The Ontario Brain Institute’s neuroinformatics platform, Brain-CODE, is achieving just that for global brain disorder research – recently launching their third clinical…
Read More
Excerpt from the Press Release: A Chester County biopharmaceutical company has submitted an application with the Food and Drug Administration to begin human testing of its experimental “antibody cocktail” as a Covid-19 treatment. Exton-based Immunome said Wednesday it expects its antibody cocktail, known as IMM-BCP-01, can neutralize the recently discovered omicron variant. “Immunome designed its…
Read More
After three years of navigating the ups and downs of building a new company, the founder and CEO of Summit Nanotech accepted the prize virtually at MaRS Climate Impact. Excerpt from the Press Release: Amanda Hall is now $1 million closer to helping Canada reach its net-zero goals. Today, Hall, founder and CEO of Calgary-based startup Summit…
Read More
— Collaboration leverages imaging, diagnostic and multiomic expertise to identify new, significant biomarkers to improve the detection of breast cancer Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Dec. 1, 2021 /PRNewswire/ — Freenome, a privately held biotech company, announced a partnership with Siemens Healthineers to collaborate in multiomics and radiomic breast cancer diagnostics to identify…
Read More
Lungs among most common site for metastatic tumors Excerpt from the Press Release: HAYWARD, Calif.–(BUSINESS WIRE)–RefleXion Medical, Inc., a therapeutic oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the company Breakthrough Device Designation for its biology-guided radiotherapy* (BgRT) for use in treating lung tumors. The breakthrough potential of BgRT lies…
Read More
Growing CRISPR genome editing portfolio supports researchers on path to future therapeutic applications Excerpt from the Press Release: CARLSBAD, Calif., Nov. 30, 2021 /PRNewswire/ — For research applications requiring highly precise genome editing, including engineering CAR T cells and creating cellular models for disease discovery, the Invitrogen TrueCut HiFi Cas9 Protein* significantly minimizes off-target events while retaining maximum on-target…
Read More
Advancement of first program from Axial platform into a randomized Phase 2b clinical trial signifies key milestone for company Trial is enrolling approximately 195 autistic adolescents at clinical trial sites in the United States, Australia and New Zealand Phase 2 trial is based on positive results from open-label Phase 1b/2a trial that demonstrated a favorable…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?